The Filing Desk

Siga Technologies vs ARS Pharmaceuticals

Siga Technologies SIGA · ARS Pharmaceuticals SPRY · Pharmaceuticals

Siga Technologies reported revenue of $95 million in fiscal 2025, about the same as ARS Pharmaceuticals' $84 million in fiscal 2025. Siga Technologies' revenue fell 31.8% in its latest year, and ARS Pharmaceuticals' fell 5.5%. Siga Technologies had an operating margin of 25.1%, against -212.9% at ARS Pharmaceuticals. Free cash flow was $43 million at Siga Technologies and −$171 million at ARS Pharmaceuticals.

Side by side

Siga TechnologiesARS Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$95M$84M
Revenue growth−31.8%−5.5%
Revenue growth a year, last 5 years−5.4%—
Gross margin68.6%—
Operating margin25.1%−212.9%
Net margin24.6%−203.2%
Free cash flow$43M−$171M
Free cash flow margin45.6%−203.1%
Return on capital34.8%—
Net debt to EBITDA−6.4x—
Dividends and buybacks$43M$0M
Change in diluted share count−0.1%−3.7%
Last close$2.65$3.36
P/E at the last close——
Insider trades, last 12 months—sold $283,550
Piotroski F-score5 of 92 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Siga TechnologiesARS Pharmaceuticals
Operating margin
Percent of revenue
Siga TechnologiesARS Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Siga TechnologiesARS Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Siga Technologies and ARS Pharmaceuticals pages.